Journal article
Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium
Cancer causes & control, v 24(1), pp 125-134
01 Jan 2013
PMID: 23160945
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Studies of smoking and risk of non-Hodgkin lymphoma (NHL) have yielded inconsistent results, possibly due to subtype heterogeneity and/or genetic variation impacting the metabolism of tobacco-derived carcinogens, including substrates of the N-acetyltransferase enzymes NAT1 and NAT2.
We conducted a pooled analysis of 5,026 NHL cases and 4,630 controls from seven case-control studies in the international lymphoma epidemiology consortium to examine associations between smoking, variation in the N-acetyltransferase genes NAT1 and NAT2, and risk of NHL subtypes. Smoking data were harmonized across studies, and genetic variants in NAT1 and NAT2 were used to infer acetylation phenotype of the NAT1 and NAT2 enzymes, respectively. Pooled odds ratios (ORs) and 95 % confidence intervals (95 % CIs) for risk of NHL and subtypes were calculated using joint fixed effects unconditional logistic regression models.
Current smoking was associated with a significant 30 % increased risk of follicular lymphoma (n = 1,176) but not NHL overall or other NHL subtypes. The association was similar among NAT2 slow (OR 1.36; 95 % CI 1.07-1.75) and intermediate/rapid (OR 1.27; 95 % CI 0.95-1.69) acetylators (p (interaction) = 0.82) and also did not differ by NAT1*10 allelotype. Neither NAT2 phenotype nor NAT1*10 allelotype was associated with risk of NHL overall or NHL subtypes.
The current findings provide further evidence for a modest association between current smoking and follicular lymphoma risk and suggest that this association may not be influenced by variation in the N-acetyltransferase enzymes.
Metrics
Details
- Title
- Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium
- Creators
- Todd M. Gibson - National Institutes of HealthKarin E. Smedby - Karolinska InstitutetChristine F. Skibola - University of California, BerkeleyDavid W. Hein - University of Louisville HospitalSusan L. Slager - Mayo Clinic in FloridaSilvia de Sanjose - Institut Català d'OncologiaClaire M. Vajdic - UNSW SydneyYawei Zhang - Yale UniversityBrian C-H. Chiu - University of ChicagoSophia S. Wang - City Of Hope National Medical CenterHenrik Hjalgrim - Statens Serum InstitutAlexandra Nieters - University of FreiburgPaige M. Bracci - University of California, San FranciscoAnne Kricker - The University of SydneyTongzhang Zheng - Yale UniversityCarol Kolar - University of Nebraska Medical CenterJames R. Cerhan - Mayo Clinic in FloridaHatef Darabi - Karolinska InstitutetNikolaus Becker - German Cancer Research CenterLucia Conde - University of California, BerkeleyTheodore R. Holford - Yale UniversityDennis D. Weisenburger - University of Nebraska Medical CenterAnneclaire J. De Roos - Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South AfricaKatja Butterbach - German Cancer Research CenterJacques Riby - University of California, BerkeleyWendy Cozen - University of Southern CaliforniaYolanda Benavente - Institut Català d'OncologiaCasey Palmers - University of California, BerkeleyElizabeth A. Holly - University of California, San FranciscoJoshua N. Sampson - National Institutes of HealthNathaniel Rothman - National Institutes of HealthBruce K. Armstrong - The University of SydneyLindsay M. Morton - National Institutes of Health
- Publication Details
- Cancer causes & control, v 24(1), pp 125-134
- Publisher
- Springer Nature
- Number of pages
- 10
- Grant note
- 990920 / National Health and Medical Research Council, Australia; National Health and Medical Research Council (NHMRC) of Australia CA069269-01; CA92153-01 / National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) PI11/01810; AGAUR_SGR01465; CIBERESP 06/06/0073 / Spanish Ministry of Health FISS grant R01CA069269; R01CA092153 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) 090659 / Swedish Cancer Society FSS 09-63424 / Danish Medical Research Council; UK Research & Innovation (UKRI); Medical Research Council UK (MRC)
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Environmental and Occupational Health
- Web of Science ID
- WOS:000312778000014
- Scopus ID
- 2-s2.0-84871795082
- Other Identifier
- 991020099508004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Oncology
- Public, Environmental & Occupational Health